0000905718-20-000254.txt : 20200214 0000905718-20-000254.hdr.sgml : 20200214 20200214163825 ACCESSION NUMBER: 0000905718-20-000254 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 GROUP MEMBERS: ABINGWORTH BIOVENTURES V, LP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CHIASMA, INC CENTRAL INDEX KEY: 0001339469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88962 FILM NUMBER: 20621031 BUSINESS ADDRESS: STREET 1: 460 TOTTEN POND ROAD STREET 2: SUITE 530 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-928-5300 MAIL ADDRESS: STREET 1: 460 TOTTEN POND ROAD STREET 2: SUITE 530 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: CHIASMA INC DATE OF NAME CHANGE: 20050922 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Abingworth LLP CENTRAL INDEX KEY: 0001397144 IRS NUMBER: 980518585 STATE OF INCORPORATION: X0 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN BUSINESS PHONE: 44 (0)20 7534 1500 MAIL ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN SC 13G/A 1 chiasma_13gam1dec312019.htm AMENDMENT NO. 1

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 1—Exit Filing)*

 

 

Chiasma, Inc.

(Name of Issuer)

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

 

16706W102

(CUSIP Number)

 

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

 

[   ] Rule 13d-1(b)

[   ] Rule 13d-1(c)

[X] Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 
 

 

CUSIP NO.  16706W102
(1) Names of Reporting Persons.  I.R.S. Identification Nos. of Above Persons (entities only):  
 

Abingworth LLP

98-051-8585

  
(2) Check the Appropriate Box if a Member of a Group (a) [   ]  
  (b) [   ]  
     
(3) SEC Use Only
(4) Citizenship or Place of Organization
  England  
Number of Shares Beneficially Owned By Each Reporting Person With
  (5) Sole Voting Power: 0    
  (6) Shared Voting Power: 890,817*  
  (7) Sole Dispositive Power: 0    
  (8) Shared Dispositive Power: 890,817*  
       
(9) Aggregate Amount Beneficially Owned by Each Reporting Person:    890,817*
     

(10) Check if the Aggregate Amount  in Row  (9) Excludes Certain Shares (See Instructions):

[   ]

(11) Percent of Class Represented by Amount in Row (9):    2.1%*
(12) Type of Reporting Person (See Instructions):   IA
             

*Based on the information set forth in the Quarterly Report on Form 10-Q of Chiasma, Inc. (the “Issuer”) filed with the Securities and Exchange Commission on November 5, 2019, there were 42,016,403 shares of the Issuer’s common stock, par value $0.001 (the “Common Stock”), outstanding as of October 31, 2019. As of December 31, 2019 (the “Event Date”), Abingworth LLP (“Abingworth”) may be deemed to beneficially own an aggregate of 890,817 shares of Common Stock of the Issuer. The number of shares of Common Stock reported above consists of (i) 370,671 shares of Common Stock held by Abingworth Bioventures V, LP (“ABV V”); and (ii) warrants to purchase 520,146 shares of Common Stock held by ABV V which were exercisable as of, or within 60 days of, the Event Date. Abingworth, as the investment manager of ABV V, may be deemed to beneficially own the 890,817 shares of Common Stock held by ABV V. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth may be deemed to beneficially own 2.1% of the shares of Common Stock deemed issued and outstanding.

 

 
 

 

CUSIP NO.  16706W102
(1) Names of Reporting Persons.  I.R.S. Identification Nos. of Above Persons (entities only):  
  Abingworth Bioventures V, LP  
(2) Check the Appropriate Box if a Member of a Group (a) [   ]  
  (b) [   ]  
     
(3) SEC Use Only
(4) Citizenship or Place of Organization
  England  
Number of Shares Beneficially Owned By Each Reporting Person With
  (5) Sole Voting Power: 0    
  (6) Shared Voting Power: 890,817*  
  (7) Sole Dispositive Power: 0    
  (8) Shared Dispositive Power: 890,817*  
       
(9) Aggregate Amount Beneficially Owned by Each Reporting Person:    890,817*
     

(10) Check if the Aggregate Amount  in Row  (9) Excludes Certain Shares (See Instructions):

[   ]

(11) Percent of Class Represented by Amount in Row (9):    2.1%*
(12) Type of Reporting Person (See Instructions):   IA
             

*Based on the information set forth in the Quarterly Report on Form 10-Q of the Issuer filed with the Securities and Exchange Commission on November 5, 2019, there were 42,016,403 shares of Common Stock, par value $0.001, outstanding as of October 31, 2019. As of the Event Date, ABV V held (i) 370,671 shares of Common Stock of the Issuer; and (ii) warrants to purchase 520,146 shares of Common Stock which were exercisable as of, or within 60 days of, the Event Date. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, ABV V may be deemed to beneficially own 2.1% of the shares of Common Stock deemed issued and outstanding. Abingworth, as the investment manager of ABV V, may be deemed to beneficially own the 890,817 shares of Common Stock held by ABV V.

 

 
 

 


Item 1(a).  Name Of Issuer:
 

Chiasma, Inc. (the “Issuer”)

 

Item 1(b).  Address of Issuer’s Principal Executive Offices:
 

460 Totten Pond Road, Suite 530

Waltham, Massachusetts 02451

 

Item 2(a).  Name of Person Filing:
  This Schedule 13G is being filed on behalf of (i) Abingworth Bioventures V, LP (“ABV V”), and (ii) Abingworth LLP (“Abingworth” and together with ABV V, the “Reporting Persons”). As of December 31, 2019 (the “Event Date”), ABV V is the owner of record of (i) 370,671 shares of common stock (the “Common Stock”) of the Issuer; and (ii) warrants to purchase 520,146 shares of Common Stock which were exercisable as of, or within 60 days of, December 31, 2019. Abingworth, as the investment manager of ABV V, may be deemed to beneficially own the 890,817 shares of Common Stock held by ABV V.
Item 2(b).  Address of Principal Business Office or, if None, Residence:
 

The business address for Abingworth and ABV V is Princess House, 38 Jermyn Street, London, England SW1Y 6DN.

 

Item 2(c).  Citizenship:
  Abingworth LLP is a limited liability partnership organized under the laws of England. ABV V is a limited partnership organized under the laws of England.
Item 2(d).  Title of Class of Securities:
  Common Stock, par value $0.001
Item 2(e).  CUSIP No.:
  16706W102
Item 3.  If This Statement Is Filed Pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:
  Not Applicable.

 

 
 

 

Item 4.  Ownership:  
  (a)  Amount Beneficially Owned: 890,817*    
  (b)  Percent of Class: 2.1%*    
  (c)  Number of Shares as to which such person has:      
  (i)  sole power to vote or to direct the vote: 0    
  (ii)  shared power to vote or to direct the vote: 890,817*  
  (iii)  sole power to dispose or to direct the disposition of: 0    
  (iv)  shared power to dispose or to direct the disposition of: 890,817*  
           

*Based on the information set forth in the Quarterly Report on Form 10-Q of the Issuer filed with the Securities and Exchange Commission on November 5, 2019, there were 42,016,403 shares of Common Stock outstanding as of October 31, 2019. As of the Event Date, Abingworth may be deemed to beneficially own an aggregate of 890,817 shares of Common Stock of the Issuer. The number of shares of Common Stock reported above consists of (i) 520,147 shares of Common Stock held by ABV V; and (ii) warrants to purchase 520,146 shares of Common Stock held by ABV V which were exercisable as of, or within 60 days of, the Event Date. Abingworth, as the investment manager of ABV V, may be deemed to beneficially own the 890,817 shares of Common Stock held by ABV V. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth may be deemed to beneficially own 2.1% of the shares of Common Stock deemed issued and outstanding.

  

Item 5.  Ownership of Five Percent or Less of a Class
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   [X]
Item 6.  Ownership of More Than Five Percent on Behalf of Another Person
  Not Applicable.
Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
  Not Applicable.
Item 8.  Identification and Classification of Members of the Group
  Not Applicable.

 

 
 

 

Item 9.  Notice of Dissolution of Group
  Not Applicable.
Item 10.  Certification
  Not Applicable.

 

 

 
 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

February 14, 2020

 

  ABINGWORTH LLP  
     
     

 

  By:   /s/ John Heard  

 

    Name: John Heard  
    Title: Authorized Signatory  
         
     

 

     
  ABINGWORTH BIOVENTURES V, LP  
         
         

 

  By:   Abingworth LLP, its Manager  
     
     

 

  By:   /s/ John Heard  

 

    Name: John Heard  
    Title: Authorized Signatory  
         

 

 

  

 

 

Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).

 

 

 
 

 

Exhibit Index

 

Exhibit Page

A.   Joint Filing Agreement dated as of February 16, 2016 by and between Abingworth LLP and Abingworth Bioventures V, LP (incorporated by reference to Exhibit A to the Schedule 13G filed with the Securities and Exchange Commission on February 16, 2016).

 

 9